EDESA BIOTECH INC (EDSA)

Company Profile

Edesa Biotech Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. The company is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. The company is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The firm is also developing product candidates for a number of chronic dermatological and inflammatory conditions.

Company Info

EDESA BIOTECH INC

100 Spy Crt

Markham ONTARIO L3R 5H6

P: 19054751234

CEO: Pardeep Nijhawan

Employees: 16

Website: https://www.edesabiotech.com/